Overview

Cocaine Use Disorder and Cortical Dopamine

Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
0
Participant gender:
All
Summary
The goal of this study is to use [C-11]FLB 457 and amphetamine (oral, 0.5 mg/kg) to measure cortical dopamine transmission in cocaine dependent individuals and healthy controls
Phase:
Early Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Amphetamine
Cocaine
Dextroamphetamine
Dopamine
Dopamine Agents
FLB 457
Criteria
Subjects with Cocaine Dependence INCLUSION CRITERIA

1. Males or Females 18-40

2. Fulfill Diagnostic and Statistical Manual (DSM-IV) Diagnosis for Cocaine Dependence

3. Medically Healthy MAJOR EXCLUSIONS

1. Major medical, psychiatric, co-morbid drug & alcohol use disorders 2. Pregnancy or
lactation, 3. Contraindications to MRI 4. Currently employed as radiation worker; or
participation in radioactive drug research protocols within the previous year 5. Family
History of a psychotic illness or manic episode in first-degree relatives

Healthy Subjects INCLUSION CRITERIA

1. Males or Females 18-40

2. Absence of present or past psychiatric conditions (including alcohol or drug
dependence)

3. A negative urine drug screen

4. Medically Healthy

MAJOR EXCLUSIONS

1. Any medical, psychiatric, co-morbid drug & alcohol use disorders

2. Pregnancy or lactation,

3. Contraindications to MRI

4. Currently employed as radiation worker; or participation in radioactive drug research
protocols within the previous year

5. Family History of a psychotic illness or manic episode, or drug and alcohol
Abuse/Dependence in first-degree relatives